Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
September 27, 2024 09:35 ET
|
Regeneron Pharmaceuticals, Inc.
Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...
Nuclear Medicine Market Projected Growth at 9.2% CAGR to Reach USD 11.4 billion by 2031 | Exclusive Research Report by Transparency Market Research Inc.
September 23, 2024 06:58 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 23, 2024 (GLOBE NEWSWIRE) -- According to a report published by Transparency Market Research, the global nuclear...
Noah Medical Shares Diagnostic Confidence of its Galaxy Users at AABIP 2024
August 15, 2024 08:00 ET
|
Noah Medical
Noah Medical to share field results, deliver interactive simulations and host multiple events for its Galaxy System at AABIP 2024
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
July 03, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
May 31, 2024 01:05 ET
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
May 31, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
February 23, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in...
Endoscopy Devices Market revenue to surpass USD 52 Billion by 2036, says Research Nester
February 13, 2024 06:30 ET
|
Research Nester
New York , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The global endoscopy devices market size is projected to grow at a CAGR of over 5% from 2024 to 2036. The market is expected to garner a revenue of USD...
Central California’s Community Regional Medical Center is the First in the State to Offer Next Generation Robotic Bronchoscopy for Early Diagnosis and Treatment of Lung Cancer
January 30, 2024 08:00 ET
|
Community Regional Medical Center
Community Regional Medical Center is the First in California to Offer Next Generation Robotic Bronchoscopy for Early Diagnosis and Treatment of Lung Cancer
Blackford Partners With Oxipit to Expand Chest X-Ray AI Solution Offering
November 22, 2023 03:00 ET
|
Blackford
Blackford Partners With Oxipit To Expand Chest X-Ray AI Solution Offering